Glutathione PEGylated liposomes: Pharmacokinetics and delivery of cargo across the blood-brain barrier in rats

Journal of Drug Targeting

Volumn 22, Issue 5, 2014, Pages 460-467

  Rip, Jaap ^a   Chen, Linda ^a   Hartman, Robin ^b   Van Den Heuvel, Angelique ^a   Reijerkerk, Arie ^a   Van Kregten, Joan ^a   Van Der Boom, Burt ^a   Appeldoorn, Chantal ^a   De Boer, Marco ^a   Maussang, David ^a   De Lange, Elizabeth C M ^b   Gaillard, Pieter J ^a  

^a BBB Technologies BV   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Biodistribution; Carboxyfluorescein; Drug delivery; Drug targeting; Microdialysis; Stability

Indexed keywords

CARBOXYFLUORESCEIN; GLUTATHIONE; LIPOSOME; 6-CARBOXYFLUORESCEIN; DRUG CARRIER; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN HOMOGENATE; BRAIN PERFUSION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PARTICLE SIZE; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CELL LINE; DRUG CARRIERS; DRUG STABILITY; ENDOTHELIAL CELLS; FLUORESCEINS; FLUORESCENT DYES; GLUTATHIONE; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; LIPOSOMES; MICRODIALYSIS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84901053100     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.888070     Document Type: Article

References (29)

1. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004; 104:29-45
2. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:323-55
3. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37:13-25
4. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6:539-46
5. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 2009;9:1519-27
6. Dickson PI. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol Ther 2009;47: S124-7
7. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555-8
8. Gaillard PJ, Visser CC, de Boer M, et al. Blood-to-brain drug delivery using nanocarriers. In: Hammarlund-Udenaes M
9. Lange ECM, Thorne R, eds. Drug delivery to the brain - physiological concepts, methodologies and approaches. Chapter 15. New York: Springer 2014 433-54
10. Riganti C, Voena C, Kopecka J, et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 2011;8:683-700
11. Huwyler J, Cerletti A, Fricker G, et al. By-passing of P-glycoprotein using immunoliposomes. J Drug Target 2002;10:73-79
12. Pinzon-Daza ML, Campia I, Kopecka J, et al. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier. Curr Drug Metab 2013;14: 625-40
13. Costantino L, Boraschi D Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today1 201217367-78
14. Zlokovic BV, Mackic JB, McComb JG, et al. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 1994;201:402-8
15. Kannan R, Kuhlenkamp JF, Jeandidier E, et al. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990;85:2009-13
16. Kannan R, Chakrabarti R, Tang D, et al. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 2000;852:374-82
17. Gaillard PJ, Appeldoorn CCM, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One 2014;9:e82331
18. Gaillard PJ, Appeldoorn CC, Rip J, et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release 2012;164: 364-9
19. Lindqvist A, Rip J, Gaillard PJ, et al. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. Mol Pharm 2013;10:1533-41
20. Mdzinarishvili A, Sutariya V, Talasila PK, et al. Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res 2013;3:309-17
21. Geldenhuys W, Mbimba T, Bui T, et al. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J Drug Target 2011;19:837-45
22. Chen RF, Knutson JR. Mechanism of fluorescence concentration quenching of carboxyfluorescein in liposomes: energy transfer to nonfluorescent dimers. Anal Biochem 1988;172:61-77
23. Roux F, Durieu-Trautmann O, Chaverot N, et al. Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol 1994;159:101-13
24. Gaillard PJ, Leyssen P, Appeldoorn CCM, et al. Development of brain-targeted liposomes with antiviral drugs for treating lethal viral encephalitis. [Abstract] Paper presented at the 8th International Conference on Cerebral Vascular Biology (CVB); 2009 Jun 28-July 2; Sendai, Japan
25. Rip J, Appeldoorn CCM, Manca FM, et al. Receptor-mediated delivery of drugs across the blood-brain barrier. Pharmacology and Toxicology of the Blood-Brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU. Brussels, Belgium; 2010. doi: 10.3389/conf.fphar.2010.02. 00025
26. Allen TM, Hansen CB, Guo LS. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1993;1150:9-16
27. Chang T, Olson JA, Proffitt RT, Adler-Moore JP. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B. Med Mycol 2010;48:430-5
28. Rosa P, Clementi F. Absorption and tissue distribution of doxorubicin entrapped in liposomes following intravenous or intraperitoneal administration. Pharmacology 1983;26:221-9
29. Haber E, Afergan E, Epstein H, et al. Route of administrationdependent anti-inflammatory effect of liposomal alendronate. J Control Release 2010;148:226-33